ArticleTranslational lung cancer research2025
The prognostic importance of the pan-immune-inflammation value (PIV) in lung cancer: a systematic review and meta-analysis.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A different perspective in trauma patients: can pan-immune-inflammation value (PIV) predict mortality?Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2026Article
- Association of Preoperative Pan-Immune-Inflammation Value with Adverse Pathology and Oncological Outcomes Following Radical Prostatectomy: A Single-Center Retrospective Study.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preliminary studies suggest that pan-immune-inflammation value (PIV) has the potential to serve as a prognostic tool for lung cancer. However, existing studies are limited by inconsistent findings regarding the impact of high PIV on patient outcomes. To provide a more comprehensive assessment, we conducted a meta-analysis to clarify the prognostic value of PIV in lung cancer. Methods: Two researchers independently searched the PubMed, Cochrane, Embase, and Web of Science databases for studies evaluating the associations between PIV and prognoses in lung cancer patients (up to July 15, 2025). Studies were included if they reported high versus low PIV and provided hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS), progression-free survival (PFS), etc. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Pooled HRs and 95% CIs were calculated to determine the associations between PIV and patient prognosis. Results: A total of ten studies comprising 1,969 patients were included. Meta-analyses demonstrated that high PIV was significantly associated with OS (HR =2.86, 95% CI: 2.23-3.65, P<0.001) and PFS (HR =2.06, 95% CI: 1.65-2.59, P<0.001) in lung cancer patients. In non-small cell lung cancer (NSCLC) patients, high PIV was significantly associated with worse OS (HR =2.76, 95% CI: 2.14-3.56, P<0.001) and PFS (HR =1.94, 95% CI: 1.55-2.42, P<0.001). In small cell lung cancer (SCLC) patients, even stronger associations were observed for OS (HR =3.47, 95% CI: 2.21-5.44, P<0.001) and PFS (HR =2.33, 95% CI: 1.63-3.33, P<0.001). Subgroup analyses further confirmed that PIV served as a critical prognostic marker for both OS and PFS. All studies were of high quality according to the NOS. Conclusions: PIV can serve as an independent prognostic biomarker for survival outcomes in lung cancer patients. Therefore, incorporating PIV into prognostic assessments may provide additional support for individualized treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.